- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00055484
A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache
A Double-Blind, Randomized, Multicenter, Parallel Dose Study to Evaluate the Safety and Efficacy of Zonisamide 150 mg and 300 mg Per Day and Placebo in Subjects With Migraine Headache
Study Overview
Detailed Description
The pharmacologic treatment of migraine may be acute (abortive, symptomatic) or preventive (prophylactic). Preventive medication is usually given daily for months or years; however, treatment may also be given in an intermittent regimen. Most migraine prophylactic medications were designed to treat other disorders, and they can be divided into three groups:
- Serotonergic or monoaminergic agents such as methysergide, which have demonstrated high degrees of effectiveness;
- Non-serotonergic drugs such as beta-blockers, tricyclic antidepressants, valproate; and
- Drugs with lesser demonstrated effectiveness, such as selective serotonin reuptake inhibitors, calcium channel antagonists, and non-steroidal anti-inflammatory drugs.
The choice of treatment must be individualized, and is influenced by contraindications, potential side effects, the need to treat associated symptoms like tension-type headache and insomnia, and drug cost.
Anticonvulsants, such as valproate, have shown significant degrees of efficacy in migraine prophylaxis when used in low doses. Considering the differences in proposed mechanisms of action of these agents, it is likely that a novel anticonvulsant such as zonisamide may also be an effective prophylactic treatment for migraine.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- Medical Affiliated Research Center
-
Mobile, Alabama, United States, 36693
- University of South Alabama Medical Ctr Department of Neurology
-
-
Arizona
-
Phoenix, Arizona, United States, 85020
- Valley Neurological Headache Clinic
-
-
Connecticut
-
Stamford, Connecticut, United States, 06902
- The New England Center for Headache
-
-
Kansas
-
Overland Park, Kansas, United States, 66215
- Radiant Research
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48104
- Michigan Head-Pain & Neurological Institute
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- Mercy Health Research
-
Springfield, Missouri, United States, 65804
- Headache Care Center
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- Neurological Associates of Tulsa
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
-
Texas
-
Austin, Texas, United States, 19107
- MetaClin Research
-
Houston, Texas, United States, 77004
- Houston Headache Clinic
-
-
Utah
-
Salt Lake City, Utah, United States, 84111
- Radiant Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION:
Subjects who meet all the following criteria will be eligible to participate in the study:
- Are men or women, between the ages of 18 and 65, inclusive.
- Satisfy diagnostic criteria for migraine headache, consistent with criteria described in Headache Classification Criteria.
- Have at least 4 migraine attacks per 28 days [each attack separated by at least 48 hours] prior to the Screening Visit and experience at least 4 migraine attacks during the Screen/Baseline Phase.
- Agree to not become pregnant during the study and agree to use an adequate method of birth control during the study such as an adequate barrier method, hormonal contraceptive, or surgical sterilization. All women of childbearing potential must have a negative pregnancy test before entering the study and during the study.
- Are able to swallow the capsules whole.
- Are willing and able to follow Investigator instructions and study procedures, complete the daily diary, and report adverse events.
EXCLUSION:
Subjects meeting any of the following criteria will not be eligible to participate in this study:
- Have required more than 3 different rescue medications for control of a single attack anytime within 3 months prior to the Screening Visit.
- Have cluster headache or chronic tension type headache and are unable to distinguish between their different types of headache.
- Have basilar or hemiplegic migraine.
- Have used triptans more than 3 times per week within 3 months prior to the Screening Visit.
- Have received botulinum toxin injection(s) within 3 months prior to the Screening Visit.
- Have taken any other prophylactic medications for migraine within 5 half-lives prior to the Baseline Visit.
- Are pregnant or lactating.
- Have a history or current diagnosis of psychiatric disorder likely to require pharmacological intervention (e.g., antidepressants, MAO inhibitors, antipsychotics, mood-stabilizers, anxiolytics) during the study.
- Have clinically unstable cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease.
- Have laboratory test results that, in the opinion of the Investigator, are clinically significant abnormalities.
- Require treatment with any medication (e.g., daily opioids, daily beta-blockers, daily non-steroidal anti-inflammatory drugs, carbonic anhydrase inhibitors, eletriptan) or herbal supplements (e.g., St. John's Wort, ginseng, ginkgo biloba, kava kava, melatonin, petadolex) that might interact adversely with, or obscure, the action of the study medication.
- Have received psychoactive medication (e.g., other anticonvulsant drugs, antidepressants, antipsychotics, anxiolytics, mood stabilizers) within 5 half-lives prior to the Baseline Visit.
- Have previously enrolled in this study or previously treated with zonisamide.
- Have previously failed an adequate trial of another antiepilepsy drug for the treatment of migraine.
- Have a history of allergy or hypersensitivity to zonisamide or other sulfonamides.
- Have a history of skin rash, without other diagnosis, associated with any medication or any medical condition.
- Have a history of nephrolithiasis.
- Have received an experimental drug or used an experimental device within 30 days of the Screening Visit.
- Have a history of drug or alcohol abuse within 12 months prior to the Screening Visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Headache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Zonisamide
Other Study ID Numbers
- AN46046-228
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine Headache
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
Ariston Pharmaceuticals, Inc.UnknownMigraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With AuraFinland, Netherlands, United Kingdom
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Click Therapeutics, Inc.Active, not recruitingMigraine | Headache | Headache, Migraine | Episodic MigraineUnited States
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Danish Headache CenterCompletedHeadache, Migraine | AuraDenmark
-
Danish Headache CenterCompletedMigraine Headache | Migraine Without AuraDenmark
-
Nanfang Hospital, Southern Medical UniversityBrainClos Co., LTD.; Zhuhai Fudan Innovation InstituteNot yet recruitingCluster Headache | Migraine in Children | Tension Headache | Migraine in Adolescence | Primary HeadacheChina
-
Children's Hospital Medical Center, CincinnatiPatient-Centered Outcomes Research InstituteRecruitingMigraine | Migraine Disorders | Headache | Headache Disorders | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
Behar, Caren, M.D.UnknownMigraine | Migraine Disorders | Migraine Headache | Acute MigraineUnited States
Clinical Trials on zonisamide
-
Eisai Inc.Completed
-
Mutual Pharmaceutical Company, Inc.Completed
-
Eisai Korea Inc.Completed
-
Orexigen Therapeutics, IncCompleted
-
University of PittsburghEisai Inc.Withdrawn
-
Mutual Pharmaceutical Company, Inc.Completed
-
Elan PharmaceuticalsTerminatedBipolar Disorders
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine DependenceUnited States
-
Washington University School of MedicineUnited States Department of Defense; University of Texas; Gateway Biotechnology...TerminatedHearing Loss, Noise-InducedUnited States
-
Eisai Korea Inc.Completed